Biocryst Pharmaceuticals Inc Stock

$4.77-0.33 (-6.47%)
Updated Apr 12, 2024
BCRX Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
May 1, 2024
Next Dividend

BCRX Overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BCRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BCRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BCRX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
BCRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more BCRX due diligence checks available for Premium users.

Be the first to know about important BCRX news, forecast changes, insider trades & much more!



BCRX fair value

Fair Value of BCRX stock based on Discounted Cash Flow (DCF)
Fair Value
Undervalued by
BCRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BCRX price to earnings (PE)

For valuing profitable companies with steady earnings

BCRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

BCRX's financial health

Profit margin

Net Income
Profit Margin
BCRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BCRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
BCRX's short-term assets ($495.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCRX's long-term liabilities ($822.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BCRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

BCRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BCRX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B

Biocryst Pharmaceuticals Stock FAQ

What is Biocryst Pharmaceuticals's quote symbol?

(NASDAQ: BCRX) Biocryst Pharmaceuticals trades on the NASDAQ under the ticker symbol BCRX. Biocryst Pharmaceuticals stock quotes can also be displayed as NASDAQ: BCRX.

If you're new to stock investing, here's how to buy Biocryst Pharmaceuticals stock.

What is the 52 week high and low for Biocryst Pharmaceuticals (NASDAQ: BCRX)?

(NASDAQ: BCRX) Biocryst Pharmaceuticals's 52-week high was $9.07, and its 52-week low was $4.45. It is currently -47.38% from its 52-week high and 7.19% from its 52-week low.

How much is Biocryst Pharmaceuticals stock worth today?

(NASDAQ: BCRX) Biocryst Pharmaceuticals currently has 206,149,929 outstanding shares. With Biocryst Pharmaceuticals stock trading at $4.77 per share, the total value of Biocryst Pharmaceuticals stock (market capitalization) is $983.34M.

Biocryst Pharmaceuticals stock was originally listed at a price of $7.00 in Dec 31, 1997. If you had invested in Biocryst Pharmaceuticals stock at $7.00, your return over the last 26 years would have been -31.86%, for an annualized return of -1.46% (not including any dividends or dividend reinvestments).

How much is Biocryst Pharmaceuticals's stock price per share?

(NASDAQ: BCRX) Biocryst Pharmaceuticals stock price per share is $4.77 today (as of Apr 12, 2024).

What is Biocryst Pharmaceuticals's Market Cap?

(NASDAQ: BCRX) Biocryst Pharmaceuticals's market cap is $983.34M, as of Apr 14, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biocryst Pharmaceuticals's market cap is calculated by multiplying BCRX's current stock price of $4.77 by BCRX's total outstanding shares of 206,149,929.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.